Down 10%, Should You Buy the Dip on Vertex Pharmaceuticals?

Vertex Pharmaceuticals (NASDAQ: VRTX) has grown revenue and profit into the billions of dollars thanks to its expertise in the treatment of cystic fibrosis (CF). The company has developed a portfolio of drugs that has transformed the way the disease is treated -- and that's made Vertex the No. 1 player in the industry.In recent years, the biotech has expanded into other treatment areas, even scoring regulatory approval for a gene editing therapy for blood disorders and a pain management drug. All of this has made Vertex a great stock to hold over time -- for example, it's climbed more than 40% over the past three years.If you haven't yet gotten in on this growth story or aim to add to your current position, you may be on the lookout for buying opportunities. Now, with Vertex down 10% from a peak back in April, is it time to invest? Let's find out.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool